Business Context and Reporting Period
Company: Senti Biosciences Holdings, Inc. (SNTI)
Filing Type: Form 8-K (Current Report)
Date of Report: July 14, 2026
Event: Entry into a Material Definitive Agreement (Agreement and Plan of Merger).
On July 14, 2026, the Company entered into a merger agreement with a private affiliate of its largest stockholder, Celadon Partners. The transaction involves the acquisition of substantially all of the Company's existing business and pipeline by a private entity. Following the transaction, the public company will remain listed on the Nasdaq Capital Market but will operate with a streamlined structure, retaining only specific intellectual property and early-stage programs focused on its Regulator Dial technology platform.
Key Financial Metrics
Cash and Liquidity: As of June 30, 2026, the Company estimates its cash and cash equivalents at $6.5 million (unaudited). Management believes this amount, combined with additional funding, will fund operations through the expected merger closing and into approximately the fourth quarter of 2026.
Debt and Financing:
- Initial Notes: $10.0 million in Senior Secured Convertible Notes were issued to an investor on May 20, 2026.
- Additional Funding: The Merger Agreement requires the Parent or an affiliate to fund and purchase additional Senior Secured Convertible Notes in an amount equal to $6.0 million, minus net proceeds from the Company's At-The-Market (ATM) facility sales.
- Ownership Impact: If the additional $6.0 million in notes is issued and exchanged for stock, the Parent affiliate's beneficial ownership is projected to reach 62.3%.
Revenue and Profit: The filing does not provide specific revenue, profit, or margin figures for the reporting period. The Company is a pre-commercial biotechnology firm.
Material Changes and Transaction Structure
Merger Consideration: Upon closing, outstanding shares of the operating subsidiary will be cancelled and converted into Contingent Value Rights (CVRs). These CVRs entitle holders to potential future cash payments based on milestones for the product candidate SENTI-202.
Contingent Value Rights (CVRs) Milestones:
- $10.0 million: If a Biologics License Application (BLA) for SENTI-202 is filed and accepted by the FDA (or the 60-day review period passes) by the 7th anniversary of the closing.
- $20.0 million: If FDA approval of the BLA for SENTI-202 is received by the 7th anniversary of the closing.
- $30.0 million: If cumulative worldwide net sales of SENTI-202 exceed $200.0 million by the 7th anniversary of the closing.
Equity Awards: All outstanding stock options will become immediately vested and exercisable. All restricted stock units (RSUs) will become fully vested. Holders will receive CVRs upon exercise or settlement.
Termination Fee: The Company is obligated to pay a termination fee of $2.5 million to the Parent if the agreement is terminated under specific circumstances, such as entering into a Superior Company Proposal.
Guidance, Outlook, and Risks
Strategic Outlook: Post-merger, the Company plans to focus on two early-stage programs: a controllable gene therapy for Rett Syndrome and armored tumor-infiltrating lymphocytes (TILs) for solid tumors, both leveraging the Regulator Dial platform.
Timeline:
- Proxy Statement: Expected to be filed within 30 business days of the agreement (by mid-August 2026).
- Stockholder Meeting: Scheduled for August 18, 2026 (virtual).
- Expected Closing: Third quarter of 2026.
- Outside Date: The agreement may be terminated if not completed by December 31, 2026.
Risks and Contingencies:
- Transaction Risk: The merger is subject to stockholder approval, regulatory approvals, and customary closing conditions. There is no assurance the transaction will close.
- Milestone Risk: There is no assurance that the milestones for the CVRs will be achieved, meaning the CVRs may expire worthless.
- Liquidity Risk: The Company's ability to maintain its Nasdaq listing post-merger is contingent on receiving sufficient capital funding.
- Change in Control: The transaction results in a significant change in control, with the Parent affiliate potentially owning up to 77.5% of the common stock if the maximum additional notes are issued and exchanged.
Investor Verification Checklist
- Proxy Statement Review: Verify the final terms of the merger and the specific voting requirements in the upcoming Schedule 14A proxy statement.
- CVR Valuation: Assess the probability of SENTI-202 achieving the specific regulatory and commercial milestones required to trigger the $60 million total potential payout.
- Liquidity Runway: Confirm the actual cash balance and burn rate in the upcoming audited quarterly report to ensure operations can be funded through the merger closing.
- Stockholder Approval: Monitor the outcome of the August 18, 2026, stockholder meeting, as the transaction is contingent on majority approval.
- ATM Facility Usage: Track any sales under the At-The-Market facility, as proceeds will reduce the $6.0 million additional funding obligation from the Parent.